Chapter

Heparan Sulfate Proteoglycan in Inflammation and Angiogenesis

DOI: 10.1007/978-3-642-16833-8_1

ABSTRACT Heparan sulfate is a linear polysaccharide composed of glucosamine and uronic acid (glucuronic acid or iduronic acid) disaccharide
repeats with various types of sulfation modifications. More than 26 enzymes participate in the biosynthesis of heparan sulfate,
which includes two major steps of chain polymerization and chain modification. The chain modification steps proceed sequentially
but are incomplete, resulting in enormous structural diversity in mature heparan sulfate. In tissues, heparan sulfate covalently
attaches to core proteins to form heparan sulfate proteoglycans, and are abundant at the cell surface and in the extracellular
matrix. Studies have demonstrated that heparan sulfate interacts with growth factors, growth factor binding proteins, extracellular
proteases, protease inhibitors, chemokines, morphogens, and adhesive proteins to critically regulate cell functions under
both physiological and pathological conditions. In this chapter, I will review our current understanding of the cellular and
molecular mechanisms, and the structure–function relationship of heparan sulfate in the regulation of inflammation and angiogenesis,
with particular focus on the regulatory roles of heparan sulfate on the key inflammatory molecules, selectin and chemokine,
and on the vascular endothelial growth factor, the master proangiogenic factor of angiogenesis.

0 Bookmarks
 · 
155 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The anti-inflammatory properties of a heparin-like compound from the shrimp Litopenaeus vannamei are related. Besides reducing significantly (p<0.001) the influx of inflammatory cells to injury site in a model of acute inflammation, shrimp heparin-like compound was able to reduce the matrix metalloproteinase (MMPs) activity in the peritoneal lavage of inflamed animals. Moreover, this compound also reduced almost 90% the activity of MMP-9 secreted by human activated leukocytes. Negligible anti-coagulant activities in aPPT assay and a poor bleeding potential make this compound a better alternative than mammalian heparin as a possible anti-inflammatory drug.
    Bioorganic & medicinal chemistry 09/2008; 16(21):9588-95. · 2.82 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Fondaparinux is a synthetic pentasaccharide that selectively inhibits factor Xa (FXa) in an antithrombin-dependent fashion. This newly developed anticoagulant is used in the prevention and treatment of venous thromboembolism. Recently, we showed that fondaparinux reduces inflammation and protects the kidney from ischemia-reperfusion (I/R) injury. However, the relative contributions of the anticoagulant and anti-inflammatory activities of fondaparinux to the observed protection is unknown. To address this, we chemically modified fondaparinux to abolish its affinity for antithrombin and analyzed the effect of this non-anticoagulant (NAC)-pentasaccharide on binding of U937 cells to P-selectin in vitro and on inflammation in a murine model of kidney I/R injury. NAC-pentasaccharide was as effective as fondaparinux at inhibiting the binding of U937 cells to P-selectin. In addition, NAC-pentasaccharide significantly reduced IL-6 and MIP-2 expression and injury in the kidney I/R model. These findings indicate that the anti-inflammatory activity of fondaparinux can be dissociated from its anticoagulant activity and that NAC-pentasaccharide is protective in kidney I/R injury.
    Thrombosis and Haemostasis 01/2007; 96(6):802-6. · 6.09 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Heparan sulfate proteoglycans are integral components of the extracellular matrix that surrounds all mammalian cells. In addition to providing structural integrity, they act as a storage depot for a variety of heparan sulfate (HS)-binding proteins, including growth factors and chemokines. Heparanase is a matrix-degrading enzyme that cleaves heparan sulfate side chains from the core proteoglycans, thus liberating such HS-binding proteins, as well as potentially contributing to extracellular matrix degradation. Here, we report that heparanase mRNA and protein expression are increased in the neoplastic stages progressively unfolding in a mouse model of multistage pancreatic islet carcinogenesis. Notably, heparanase is delivered to the neoplastic lesions in large part by infiltrating Gr1+/Mac1+ innate immune cells. A sulfated oligosaccharide mimetic of heparan sulfate, PI-88, was used to inhibit simultaneously both heparanase activity and HS effector functions. PI-88 had significant effects at distinct stages of tumorigenesis, producing a reduction in the number of early progenitor lesions and an impairment of tumor growth at later stages. These responses were associated with decreased cell proliferation, increased apoptosis, impaired angiogenesis, and a substantive reduction in the number of invasive carcinomas. In addition, we show that the reduction in tumor angiogenesis is correlated with a reduced association of VEGF-A with its receptor VEGF-R2 on the tumor endothelium, implicating heparanase in the mobilization of matrix-associated VEGF. These data encourage clinical applications of inhibitors such as PI-88 for the many human cancers where heparanase expression is elevated or mobilization of HS-binding regulatory factors is implicated.
    Oncogene 07/2005; 24(25):4037-51. · 7.36 Impact Factor